CA3165187A1 - Methods for treatment of cancer with an anti-tigit antagonist antibody - Google Patents

Methods for treatment of cancer with an anti-tigit antagonist antibody Download PDF

Info

Publication number
CA3165187A1
CA3165187A1 CA3165187A CA3165187A CA3165187A1 CA 3165187 A1 CA3165187 A1 CA 3165187A1 CA 3165187 A CA3165187 A CA 3165187A CA 3165187 A CA3165187 A CA 3165187A CA 3165187 A1 CA3165187 A1 CA 3165187A1
Authority
CA
Canada
Prior art keywords
rnethod
subject
dose
weeks
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3165187A
Other languages
English (en)
French (fr)
Inventor
Catherine LAI
Janet LAU
Anthony Jongha LEE
Shi Li
Yvonne Gail LIN-LIU
Christina Jeanne MATHENY
Diana Mendus
Raymond D. Meng
Anh NGUYEN DUC
Jilpa Bhupendra PATEL
Thinh Quang Pham
Isabelle Anne ROONEY
Heather Blythe STEVENS
Sarah Marie TROUTMAN
Lijia Wang
Yulei Wang
Patrick Georges Robert WILLIAMS
Benjamin Wu
Yibing Yan
Aijing ZHANG
Xiaosong Zhang
Marcus Dale BALLINGER
Hila BARAK
Elizabeth Alexandra BENNETT
Marcela Lucia CASTRO
Edward Namserk CHA
Hui Min Phyllis CHAN
Stephen CHUI
Christopher Roland COTTER
Viraj Vinay DEGAONKAR
Barbara Jennifer Gitlitz
Tien HOANG
Kimberly Mayumi KOMATSUBARA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/024526 external-priority patent/WO2021194481A1/en
Priority claimed from PCT/US2020/049415 external-priority patent/WO2022050954A1/en
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Publication of CA3165187A1 publication Critical patent/CA3165187A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
CA3165187A 2020-01-27 2021-01-26 Methods for treatment of cancer with an anti-tigit antagonist antibody Pending CA3165187A1 (en)

Applications Claiming Priority (29)

Application Number Priority Date Filing Date Title
US202062966448P 2020-01-27 2020-01-27
US62/966,448 2020-01-27
US202062985822P 2020-03-05 2020-03-05
US62/985,822 2020-03-05
US202062994272P 2020-03-24 2020-03-24
PCT/US2020/024526 WO2021194481A1 (en) 2020-03-24 2020-03-24 Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
USPCT/US2020/024526 2020-03-24
US62/994,272 2020-03-24
US202063059054P 2020-07-30 2020-07-30
US63/059,054 2020-07-30
US202063059960P 2020-07-31 2020-07-31
US63/059,960 2020-07-31
US202063074827P 2020-09-04 2020-09-04
US202063074807P 2020-09-04 2020-09-04
US63/074,807 2020-09-04
PCT/US2020/049415 WO2022050954A1 (en) 2020-09-04 2020-09-04 Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
US63/074,827 2020-09-04
USPCT/US2020/049415 2020-09-04
US202063085890P 2020-09-30 2020-09-30
US63/085,890 2020-09-30
US202063105198P 2020-10-23 2020-10-23
US63/105,198 2020-10-23
US202063114517P 2020-11-16 2020-11-16
US63/114,517 2020-11-16
US202063124693P 2020-12-11 2020-12-11
US63/124,693 2020-12-11
US202063127109P 2020-12-17 2020-12-17
US63/127,109 2020-12-17
PCT/US2021/015143 WO2021154761A1 (en) 2020-01-27 2021-01-26 Methods for treatment of cancer with an anti-tigit antagonist antibody

Publications (1)

Publication Number Publication Date
CA3165187A1 true CA3165187A1 (en) 2021-08-05

Family

ID=74626264

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3165187A Pending CA3165187A1 (en) 2020-01-27 2021-01-26 Methods for treatment of cancer with an anti-tigit antagonist antibody

Country Status (10)

Country Link
EP (1) EP4096646A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023511595A (cg-RX-API-DMAC7.html)
KR (1) KR20220133243A (cg-RX-API-DMAC7.html)
CN (1) CN115315256A (cg-RX-API-DMAC7.html)
AU (1) AU2021212662A1 (cg-RX-API-DMAC7.html)
CA (1) CA3165187A1 (cg-RX-API-DMAC7.html)
IL (1) IL294800A (cg-RX-API-DMAC7.html)
MX (1) MX2022009170A (cg-RX-API-DMAC7.html)
TW (1) TW202142230A (cg-RX-API-DMAC7.html)
WO (1) WO2021154761A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3175127A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2021257503A1 (en) * 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
KR20240028452A (ko) * 2021-07-02 2024-03-05 제넨테크, 인크. 암을 치료하기 위한 방법 및 조성물
CN118871463A (zh) * 2021-07-28 2024-10-29 基因泰克公司 用于治疗癌症的方法和组合物
JP2024532744A (ja) * 2021-08-10 2024-09-10 メルク・シャープ・アンド・ドーム・エルエルシー T1gitアンタゴニスト、pd-1アンタゴニスト、及び(1又は複数の)化学療法剤を含む治療的組合せ
US20250064794A1 (en) * 2021-08-10 2025-02-27 Eisai R&D Management Co., Ltd. A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib
WO2023040804A1 (zh) * 2021-09-14 2023-03-23 信达生物制药(苏州)有限公司 抗pd-1抗体和化疗药的药物组合及其使用方法
JP2024535793A (ja) * 2021-09-15 2024-10-02 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Pd-1に特異的に結合するタンパク質及びその医薬的使用
MX2024007749A (es) * 2021-12-22 2024-07-01 Genentech Inc Formulaciones clinicas de anticuerpos anti-tigit.
CN114181310B (zh) * 2022-02-14 2022-07-05 中山康方生物医药有限公司 抗tigit抗体、其药物组合物及用途
WO2024130026A1 (en) * 2022-12-16 2024-06-20 Elevar Therapeutics, Inc. Methods and compositions for treatment of subjects with hepatic impairments
KR20250118852A (ko) * 2022-12-23 2025-08-06 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
CN121241067A (zh) * 2023-03-31 2025-12-30 基因泰克公司 用抗tigit抗体治疗肿瘤的方法
CN116716393A (zh) * 2023-05-10 2023-09-08 首都医科大学附属北京儿童医院 用于检测caebv和im宿主差异甲基化基因的物质、试剂盒及其应用
WO2024263195A1 (en) * 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
TW202515614A (zh) 2023-08-25 2025-04-16 美商建南德克公司 治療非小細胞肺癌之方法及組成物
WO2025174933A1 (en) * 2024-02-14 2025-08-21 Genentech, Inc. Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel
CN121003695A (zh) * 2024-05-24 2025-11-25 百奥泰生物制药股份有限公司 抗tigit抗体和抗pd-1抗体联合治疗肿瘤
CN118919054B (zh) * 2024-07-12 2025-09-30 中国医学科学院肿瘤医院 基于聚类方法的特定疾病的复发概率的预测方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
KR100441557B1 (ko) 1994-07-21 2005-08-05 아크조 노벨 엔.브이. 고리형케톤과산화물조성물
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
AU7165698A (en) 1997-05-06 1998-11-27 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU1308799A (en) 1997-11-06 1999-05-31 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
CN1160338C (zh) 1998-11-19 2004-08-04 沃尼尔·朗伯公司 N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂
AU2005250484B2 (en) 2004-06-04 2011-08-11 Genentech, Inc. EGFR mutations
WO2014046730A1 (en) 2012-09-24 2014-03-27 Ventana Medical Systems, Inc. Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (alk) as a marker
JP2017515859A (ja) * 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗pd−1抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
DK3294770T4 (da) 2015-05-12 2024-05-21 Hoffmann La Roche Terapeutiske og diagnostiske fremgangsmåder til cancer
EP3303632B2 (en) 2015-05-29 2023-05-10 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US20200399376A1 (en) * 2018-02-26 2020-12-24 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies

Also Published As

Publication number Publication date
KR20220133243A (ko) 2022-10-04
JP2026116924A (ja) 2026-07-14
WO2021154761A1 (en) 2021-08-05
TW202142230A (zh) 2021-11-16
JP2023511595A (ja) 2023-03-20
MX2022009170A (es) 2022-08-17
IL294800A (en) 2022-09-01
AU2021212662A1 (en) 2022-08-11
EP4096646A1 (en) 2022-12-07
CN115315256A (zh) 2022-11-08

Similar Documents

Publication Publication Date Title
AU2022203501B2 (en) Therapeutic and diagnostic methods for cancer
EP4096646A1 (en) Methods for treatment of cancer with an anti-tigit antagonist antibody
CA3038712A1 (en) Therapeutic and diagnostic methods for cancer
CA3015528A1 (en) Therapeutic and diagnostic methods for cancer
CN107532217A (zh) 用于癌症的治疗和诊断方法
US20240424092A1 (en) Methods for treatment of cancer with an anti-tigit antagonist antibody
TWI819011B (zh) 以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法
US20240252632A1 (en) Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
TW202600167A (zh) 用抗pd-l1抗體治療癌症之方法
US20210332143A1 (en) Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
HK40016679A (en) Therapeutic and diagnostic methods for cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240703

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240829

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240927

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241223

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250128

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250128

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251219

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251219

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260106

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260218